Pharm'Up

AKTU – B. Pharm. 2nd Semester (First Year)

1 min read

• Previous Papers

AKTU – B. Pharm. 2nd Semester (First Year)

Pharm'Up

HUMAN ANATOMY AND PHYSIOLOGY-II THEORY (BP201T) HUMAN-ANATOMY-AND-PHYSIOLOGY-II (BP201T) MAY-2025 BP201T Human Anatomy and Physiology II – Theory...

Read More Read more about AKTU – B. Pharm. 2nd Semester (First Year)

Merck’s Winrevair™ Gains FDA Priority Review Following Stellar ZENITH Trial Data

3 min read

• Pharma News

Merck’s Winrevair™ Gains FDA Priority Review Following Stellar ZENITH Trial Data

Pharm'Up

Merck has revealed that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review...

Read More Read more about Merck’s Winrevair™ Gains FDA Priority Review Following Stellar ZENITH Trial Data

Novartis Reveals Phase III GCAptAIN Trial Outcomes: Cosentyx Misses Primary Target for Giant Cell Arteritis

2 min read

• Industries

Novartis Reveals Phase III GCAptAIN Trial Outcomes: Cosentyx Misses Primary Target for Giant Cell Arteritis

Pharm'Up

Novartis has disclosed the preliminary findings from its Phase III GCAptAIN study, assessing Cosentyx® (secukinumab) for the...

Read More Read more about Novartis Reveals Phase III GCAptAIN Trial Outcomes: Cosentyx Misses Primary Target for Giant Cell Arteritis

Lupin Introduces Ipratropium Bromide Nasal Spray in the U.S. Market

1 min read

• Industries

Lupin Introduces Ipratropium Bromide Nasal Spray in the U.S. Market

Pharm'Up

Global pharmaceutical leader Lupin Limited has unveiled the launch of Ipratropium Bromide Nasal Solution (Nasal Spray) in...

Read More Read more about Lupin Introduces Ipratropium Bromide Nasal Spray in the U.S. Market

Biocon Biologics Gains UK Approval for Denosumab Biosimilars

1 min read

• Industries

Biocon Biologics Gains UK Approval for Denosumab Biosimilars

Pharm'Up

Biocon Biologics Ltd. (BBL), a leading global biosimilars company and subsidiary of Biocon Ltd., has received marketing...

Read More Read more about Biocon Biologics Gains UK Approval for Denosumab Biosimilars

AKTU – B. Pharm. 1st Semester (First Year)

1 min read

• Previous Papers

AKTU – B. Pharm. 1st Semester (First Year)

Pharm'Up

HUMAN ANATOMY AND PHYSIOLOGY-I THEORY (BP101T) HUMAN-ANATOMY-AND-PHYSIOLOGY-I (BP101T) MAY-2025 BP101T Human Anatomy and Physiology I– Theory BP102T...

Read More Read more about AKTU – B. Pharm. 1st Semester (First Year)

Global Heart Disease Toll Linked to Widespread Plastic Chemical Exposure

2 min read

• Pharma News

Global Heart Disease Toll Linked to Widespread Plastic Chemical Exposure

Pharm'Up

A comprehensive study by NYU Langone Health revealed a significant link between daily exposure to di-2-ethylhexyl phthalate...

Read More Read more about Global Heart Disease Toll Linked to Widespread Plastic Chemical Exposure

Novartis Achieves Historic Approval for Pioneering Malaria Treatment for Newborns and Young Infants

2 min read

• Industries

Novartis Achieves Historic Approval for Pioneering Malaria Treatment for Newborns and Young Infants

Pharm'Up

Novartis achieved a major milestone in global child health with the Swissmedic approval of Coartem® Baby (artemether-lumefantrine),...

Read More Read more about Novartis Achieves Historic Approval for Pioneering Malaria Treatment for Newborns and Young Infants

Lupin and Zentiva Forge Strategic Partnership for Global Commercialization of Certolizumab Pegol Biosimilar

2 min read

• Industries

Lupin and Zentiva Forge Strategic Partnership for Global Commercialization of Certolizumab Pegol Biosimilar

Pharm'Up

Lupin Limited, a global pharmaceutical leader, and Zentiva Group, a prominent pan-European pharmaceutical company, announced a landmark...

Read More Read more about Lupin and Zentiva Forge Strategic Partnership for Global Commercialization of Certolizumab Pegol Biosimilar

FDA Accepts Milestone Pharma’s CRL Response for CARDAMYST Nasal Spray; PDUFA Date Set for December 2025

2 min read

• Industries

FDA Accepts Milestone Pharma’s CRL Response for CARDAMYST Nasal Spray; PDUFA Date Set for December 2025

Pharm'Up

Milestone Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has officially accepted its...

Read More Read more about FDA Accepts Milestone Pharma’s CRL Response for CARDAMYST Nasal Spray; PDUFA Date Set for December 2025